New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:38 EDTAVNRAvanir to present data related to safety and efficacy of AVP-825
Avanir Pharmaceuticals announced that data related to the safety and efficacy of AVP-825, a Breath-Powered Nasal Delivery of Powdered Sumatriptan for the acute treatment of migraine, will be presented at the American Headache Society's 56th Annual Scientific Meeting. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath-Powered delivery technology.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
07:11 EDTAVNRAvanir AVP-923 data looks better than expected, says Piper Jaffray
Piper Jaffray says the Phase II data Avanir presented for AVP-923 in Alzheimer's agitation at the American Neurological Association Monday was better than expected and could open the door for a billion dollar opportunity. It reiterates an Overweight rating on the stock with a $21 price target.
October 13, 2014
16:32 EDTAVNRAvanir Phase 2 AVP-923 study shows improvement in agitation on primary endpoint
Subscribe for More Information
07:33 EDTAVNRAmerican Neurological Association to hold annual meeting
ANA 2014: 139th Annual Meeting is being held in Baltimore on October 12-14.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use